Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03716427 · ClinicalTrials.gov registry record · Phase 1
Drug Interaction Study of CT1812 in Healthy Volunteers
A Phase 1 study, sponsored by Cognition Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03716427 is a Phase 1 study that has completed, run by Cognition Therapeutics. The registered enrollment target is 16 participants.
The verdict
NCT03716427, a Phase 1 study, has completed, sponsored by Cognition Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is Phase 1, single-center, open-label, single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of 4 probe drugs (tolbutamide, midazolam, dextromethorphan and omeprazole).
Interventions
- DRUG Omeprazole
- DRUG midazolam
- DRUG CT1812
- DRUG dextromethorphan
- DRUG tolbutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2016-11-10 |
| Est. Completion | 2017-02-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03716427
The ClinicalTrials.gov registry entry for NCT03716427 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cognition Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Omeprazole is the first listed.
NCT03716427 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03716427 about?
NCT03716427 is a clinical study titled "Drug Interaction Study of CT1812 in Healthy Volunteers". This is Phase 1, single-center, open-label, single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of 4 probe drugs (tolbutamide, midazolam, dextromethorphan and omeprazole).
What is the current status of trial NCT03716427?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2016-11-10. Estimated completion is 2017-02-15.
What interventions are being tested in trial NCT03716427?
The interventions under investigation include: Omeprazole (DRUG), midazolam (DRUG), CT1812 (DRUG), dextromethorphan (DRUG), tolbutamide (DRUG).
Who is sponsoring clinical trial NCT03716427?
This trial is sponsored by Cognition Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.